PolyPid(NASDAQ) PYPD

Market Cap$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year+49%
1 Month-4%
$5.13
-1.35%
-0.07Today
PolyPid last closing stock price
MetricPriceDate
Last closeUSD 5.202026-10-05
PolyPid stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.07%USD 5.312026-09-28
1 month-3.53%USD 5.392026-09-04
3 month-2.44%USD 5.332026-07-07
Year to date+19.82%USD 4.342025-12-31
1 year+48.57%USD 3.502025-10-03
3 year+36.48%USD 3.812023-10-06
5 year-97.65%USD 221.102021-10-06
Since inception-99.09%USD 570.002020-06-26

PolyPid Financials at a Glance

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$31.50

EPS (TTM)

-$1.48

P/E Ratio

-3.51

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$5.13

Volume

65,020.918

Open

$5.22

Previous Close

$5.20

Daily Range

$5.10 - $5.24

52-Week Range

$3.06 - $5.73

Estimated Earnings Date

N/A

PYPD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyPid

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

Industry

Pharmaceuticals

Sector

Health Care

Employees

75

CEO

Dikla Czaczkes Akselbrad, MBA, CPA

Website

www.polypid.com

PYPD Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-243.59%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-28.49%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.31M

Volume

65.02K

Avg. Volume

189.40K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

PolyPid Performance Analysis

PolyPid annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
PolyPid annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.04-10.5%
20232023-12-31USD -16.99734.6%
20242024-12-31USD -4.91-71.1%
20252025-12-31USD -2.09-57.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.29

N/A

Employees

75

N/A

Net Income

-$7.85

+0.8%

EBITDA

-$7.07

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$8.34

-68.3%

Total Debt

$1.57

+0.2%

Accounts Receivable

N/A

N/A

Inventory

$1.36

N/A

Long Term Debt

$0.28

+0.3%

Short Term Debt

$1.29

+0.2%

Return on Assets

-119.05%

+1.0%

Return on Invested Capital

-290.13%

+1.2%

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,828.74+0.01%
^DJIDJI
$51,532.64+0.01%
^IXICNASDAQ
$27,658.12+0.01%
BTCBitcoin
$85,726.00+0.00%

Questions About PYPD

What is the current price of PolyPid?

PolyPid is trading at $5.13 per share.

What is the 52-week range for PolyPid?

Over the past 52 weeks, PolyPid has traded between $3.06 and $5.73.

How much debt does PolyPid have?

As of the most recent reporting period, PolyPid reported total debt of $1.57M.

How much cash does PolyPid have on hand?

PolyPid reported $6.77M in cash and cash equivalents in its most recent financial results.

What is PolyPid’s dividend yield?

PolyPid does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services